

# Antiviral treatment for chronic hepatitis B virus infection – immune modulation or viral suppression?

E.H.C.J. Buster, H.L.A. Janssen\*

Department of Gastroenterology and Hepatology (CA 326), Erasmus Medical Centre,  
University Medical Centre Rotterdam, Rotterdam, the Netherlands,

\*corresponding author: tel.: +31 (0)10-463 59 42, fax: +31 (0)10-436 59 16,  
e-mail: h.janssen@erasmusmc.nl

## ABSTRACT

The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term. Treatment is generally recommended for patients with high serum HBV DNA and elevated ALAT, indicating the host's immune response against HBV. Induction of an HBV-specific immune response seems crucial for persistent control of HBV infection. Currently available treatment strategies can be differentiated into those that provide sustained off-treatment response and those that provide therapy maintained response. A finite treatment course with immunomodulatory agents (interferon-based therapy) results in sustained response in about one third of patients, while nucleoside analogue treatment generally requires indefinite therapy without a clear stopping point. Since nucleoside analogues are well tolerated, prolonged therapy is feasible, but a major drawback is the considerable risk of developing antiviral resistance, which occurs most frequently in lamivudine-treated patients and to a lesser extent during adefovir or entecavir therapy. In our opinion, treatment with peginterferon should therefore be considered first-line therapy in eligible patients with a high likelihood of response based on serum HBV DNA, ALAT and HBV genotype. Patients not responding to PEG-IFN therapy or not eligible for peginterferon therapy should be treated with nucleos(t)ide analogues.

## KEYWORDS

Adefovir, interferon, lamivudine, nucleoside analogues, peginterferon


## INTRODUCTION

Worldwide more than two billion people have been infected with hepatitis B virus (HBV) and chronic HBV infection affects about 400 million people.<sup>1,2</sup> It is estimated that more than 500,000 people die annually due to HBV-associated liver disease, largely because of cirrhosis and/or hepatocellular carcinoma.<sup>3</sup> Despite the availability of safe and effective vaccines for more than two decades, HBV infection is still a global health problem. The approach to the treatment of chronic HBV infection has dramatically changed over the past decade and the current availability of a number of antiviral drugs adds to the complexity of management of chronic HBV. This paper provides a practical review of available treatment options to guide decisions on optimal therapy based on both patient and treatment characteristics. The main focus will be on deciding between a finite course of immunomodulatory therapy with (pegylated) interferon (IFN) or prolonged viral suppression with nucleoside analogues.

### Natural history

In adults, infection with HBV is usually asymptomatic and results in chronic infection in <5% of patients.<sup>3</sup> Infection at younger age is associated with a higher risk of chronic infection, up to 90% in the setting of perinatal transmission.<sup>3</sup> Patients can present with chronic HBV in one of four phases of infection (*figure 1*).<sup>4</sup> In the immunotolerant phase of infection, hepatitis B surface

**Figure 1.** Natural history of chronic hepatitis B infection



This figure shows the phases in chronic hepatitis B infection. Patients can be categorised in one of these four phases depending on serum HBV DNA and ALAT, and the presence or absence of HBeAg and anti-HBe.

antigen (HBsAg) and hepatitis B e antigen (HBeAg) are present and HBV DNA levels are high,  $>1.0 \times 10^5$  copies per millilitre (c/ml). Hepatic inflammation is mild with normal or minimally elevated serum alanine aminotransferase (ALAT) levels and minimal necroinflammation on liver histology. In the immuno-active phase, HBsAg, HBeAg and high HBV DNA are still present, while an active immune response results in hepatic inflammation with elevation of serum ALAT. In the immune-clearance phase HBeAg is present and HBV DNA levels can be high or fluctuating. Liver inflammation is present with elevated serum ALAT and active inflammation on liver histology; loss of HBeAg and seroconversion to anti-HBe can occur. The immune-control phase follows HBeAg seroconversion. In this phase hepatic inflammation is minimal and HBV DNA levels are low due to continuous host immune response. This phase of infection is also referred to as the 'inactive carrier state'. In an increasing number of patients with HBeAg-negative HBV, biochemical and histological activity recur and HBV DNA levels are high, resulting in HBeAg-negative chronic hepatitis. These patients often originate from the Mediterranean basin, and are infected with hepatitis B variants that hamper the production of HBeAg. The most commonly described mutation is a G to A transition at position 1896 of the precore region. Three major patterns of HBeAg-negative HBV can be distinguished: a recurrent form with exacerbations and periods of remission (45%), an unremitting form (36%), and an unremitting form with acute exacerbations (20%).<sup>5</sup> Despite the occurrence of HBeAg-negative HBV, HBeAg seroconversion is still usually associated with improved long-term outcome and therefore considered an important event in the natural course of chronic HBV.<sup>6</sup>

Spontaneous HBeAg seroconversion occurs in 8 to 15% of patients in Western countries.<sup>3</sup> Before achieving HBeAg seroconversion many patients have episodes of acute exacerbation.<sup>7,8</sup> The chance of HBeAg seroconversion during acute exacerbation increases with increasing serum ALAT levels, to 45% in patients with ALAT  $>5$  times the upper limit of normal (ULN).<sup>9,10</sup>

#### Progression to cirrhosis

The overall annual incidence of progression to cirrhosis in chronic HBV-infected patients is about 6%, with a cumulative five-year probability of 20%.<sup>11</sup> In HBeAg-positive patients the annual incidence of progression to cirrhosis is 2 to 5%.<sup>3</sup> Factors associated with an increased rate of progression to cirrhosis include high serum HBV DNA, coinfection with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV), recurrent episodes of acute exacerbation and severe necroinflammation at diagnosis.<sup>3,12-14</sup> The probability of survival five years after diagnosis of cirrhosis is 84%.<sup>15</sup> Hepatic decompensation occurs at an annual rate of about 3% in cirrhotic patients, with a five-year cumulative incidence of 16%.<sup>3</sup> Development of decompensated cirrhosis is associated with survival of only 35% at five years.<sup>16</sup>

#### Hepatocellular carcinoma

The development of hepatocellular carcinoma (HCC) is a major global health problem.<sup>17</sup> Cirrhosis predisposes to HCC and the majority of patients with HCC have underlying cirrhosis (80 to 90%).<sup>18</sup> The annual incidence of HCC in European patients with chronic hepatitis B is about 2.2% in patients with compensated cirrhosis, with a five-year cumulative incidence of about 10%.<sup>18</sup> In Asians the incidence of HCC is higher with an annual rate of 3.2% in patients with cirrhosis and a five-year cumulative incidence of 15%.<sup>18</sup> Predictors of the occurrence of HCC in cirrhotic patients include older age, male sex, sustained activity of liver disease, high HBV DNA level, HBeAg positivity, coinfection with HCV or HIV and alcohol abuse.<sup>18-21</sup> Screening for HCC, with monitoring of  $\alpha$ -fetoprotein levels and six-monthly radiographic examination should be considered for patients at increased risk of developing HCC.<sup>22</sup>

#### Hepatitis B virus genotypes

Hepatitis B virus has been classified into eight genotypes (A-H) (table 1).<sup>23-25</sup> Genotypes A and D are most frequently observed in Europe and North America, while genotypes B and C are prevalent in Asia. Compared with genotype C, genotype B is associated with spontaneous HBeAg seroconversion at younger age, less active liver disease, a slower rate of progression to cirrhosis and less frequent development of HCC.<sup>26-28</sup> Findings on the relationship of other genotypes with clinical outcome are contradictory.<sup>29,30</sup> HBV genotype has been reported to be associated with

response to (pegylated) interferon treatment. HBeAg seroconversion was found to occur more often in patients with genotype A and B than in those with genotype C and D.<sup>31-33</sup> Genotype B seems to have a better virological response to lamivudine than genotype C.<sup>34</sup>

### Hepatitis B virus immunopathogenesis

Hepatitis B virus specific T-cell response plays a crucial role in control of viral infection. A vigorous, polyclonal and multispecific peripheral blood T-cell response can be observed in patients with acute self-limiting HBV.<sup>35,36</sup> Activated HBV-specific helper and cytotoxic T-cells are still present several years after recovery from acute hepatitis B and seem to be maintained by continuous stimulation by minute amounts of persisting virus. Therefore, resolution of disease does not imply complete eradication of infection but merely reflects the capacity of HBV-specific T-cells to persistently control HBV infection.<sup>37,38</sup> Viral persistence is believed to be associated with functional tolerance of helper

T-lymphocytes and cytotoxic T-lymphocytes to HBV.<sup>39</sup> In chronic HBV-infected patients levels of HBV-specific helper T-cells and cytotoxic T-lymphocytes are generally very low or undetectable.<sup>35</sup>

### MANAGEMENT OF CHRONIC HEPATITIS B VIRUS INFECTION

#### Patients eligible for antiviral treatment

Antiviral treatment is, in general, not recommended for patients with acute hepatitis B, since the outcome of acute hepatitis B is good in the vast majority of immunocompetent adult patients. For HBeAg-positive patients, treatment is recommended for chronically infected patients with HBV DNA  $>10^5$  c/ml and persistence of elevated ALAT levels (more than twice the upper limit of normal) over a three to six month period (*table 2*). An HBV DNA level of  $10^4$  c/ml should be used for HBeAg-

**Table 1.** Geographical distribution of hepatitis B virus genotypes

Genotype	Subtypes	Geographical distribution
A	adw2, ayw1	North-Western Europe, Spain, Poland, USA, Central Africa, India, Brazil
B	adw2, ayw1	Southeast Asia, Taiwan, Japan, Indonesia, China, Hong Kong, Vietnam, Thailand
C	adw2, adrq+, adrq-, ayr	Far East Asia, Taiwan, Japan, Korea, China, Hong Kong, Thailand, Indonesia, Polynesia, Solomon Islands, Vietnam, India, Australia, USA, Brazil
D	ayw2, ayw3	Mediterranean area, Albania, Middle East, Turkey, Iran, India, Spain, Czech, Russia, USA, Brazil, Solomon Islands
E	ayw4	West Africa
F	adw4q-, adw2, ayw4	Central and South America, Bolivia, Venezuela, Argentina, Brazil, Polynesia, Alaska
G	adw2	France, Germany, USA
H	adw4	Central and South America

This table shows the association of eight hepatitis B virus genotypes with various subtypes and geographic distribution according to genotype.

**Table 2.** Management strategies in chronic hepatitis B

Stage of disease	HBeAg status	ALAT	HBV DNA (c/ml)	Management strategy
Compensated liver disease	HBeAg positive	$\geq 2x$ ULN	$\geq 1.0 \times 10^5$	Antiviral treatment indicated (PEG-IFN or nucleos(t)ide analogue therapy)
		$< 2x$ ULN	$\geq 1.0 \times 10^5$	3 monthly monitoring, consider liver biopsy (consider treatment in case of active necroinflammation)
		$< 2x$ ULN	$< 1.0 \times 10^5$	3 monthly monitoring
	HBeAg negative	$\geq 2x$ ULN	$< 1.0 \times 10^5$	Exclude other causes of hepatitis, consider liver biopsy
		$\geq 2x$ ULN	$\geq 1.0 \times 10^4$	Antiviral treatment indicated (PEG-IFN or nucleos(t)ide analogue therapy)
		$< 2x$ ULN	$\geq 1.0 \times 10^4$	3-6 monthly monitoring, consider liver biopsy (consider treatment in case of active necroinflammation)
Decompensated liver disease	HBeAg positive	$< 2x$ ULN	$< 1.0 \times 10^4$	6-12 monthly monitoring
		$\geq 2x$ ULN	$< 1.0 \times 10^4$	Exclude other causes of hepatitis, consider liver biopsy
	HBeAg negative	Any level	Positive by PCR ( $>300$ )	Antiviral treatment indicated (nucleos(t)ide analogue therapy)
		Any level	Positive by PCR ( $>300$ )	Antiviral treatment indicated (nucleos(t)ide analogue therapy)

This table shows management strategies for chronic hepatitis B infected patients based on the stage of liver disease, HBeAg status, HBV DNA level and serum alanine aminotransferase (ALAT). For patients with no treatment indication at this moment, monitoring of these variables at various intervals is recommended. ULN = upper limit of normal; PCR = polymerase chain reaction.

negative patients, since this level was found to differentiate patients from having HBeAg-negative chronic hepatitis or being inactive carriers.<sup>40</sup> In HBeAg-negative patients with HBV DNA  $>10^4$  or HBeAg-positive patients with HBV DNA  $>10^5$  c/ml, and presence of normal ALAT levels, a liver biopsy may be considered to guide decisions on antiviral therapy.<sup>41</sup> In case of active necroinflammation, antiviral treatment can be considered. In patients with histological or clinical evidence of advanced fibrosis or cirrhosis, treatment with lamivudine has shown to reduce progression to decompensated liver disease and hepatocellular carcinoma.<sup>42</sup> Since serum HBV DNA has become increasingly important in the management of chronic HBV, use of standardised assays for quantification of HBV DNA is essential.

Patients who are currently not candidates for treatment should be monitored, as their condition may run a fluctuating course and treatment may be needed on future examinations (table 2). For HBeAg-positive patients with high serum HBV DNA but normal ALAT levels, monitoring ALAT with three monthly intervals is recommended, with more frequent monitoring when ALAT levels become elevated. Testing for liver chemistry should be performed every six to twelve months to account for reactivation of liver disease in HBeAg-negative patients with low serum HBV DNA and normal ALAT levels.<sup>43</sup>

### Goals of therapy

Sustained viral suppression is the key to reduce hepatic necroinflammation and progression of liver fibrosis. Since elimination of HBV infection (HBsAg seroconversion) can only be achieved in a small proportion of patients with currently available antiviral agents, permanent suppression of HBV is the primary goal of treatment. Further, seroconversion to anti-HBe should be pursued in HBeAg-positive patients since this is associated with improved outcome.<sup>44,45</sup>

### Definition of response to antiviral treatment

Response to antiviral treatment can be defined as sustained off-therapy or therapy-maintained response. Biochemical response is defined as decrease in serum ALAT to within the normal range. A virological response is defined as HBV DNA  $<10^5$  c/ml or HBV DNA negativity by sensitive molecular assays, and loss of HBeAg in previously positive patients.<sup>3</sup> Histological response is best defined as a two-point decrease in necroinflammatory score with no worsening of fibrosis. Complete response is defined as loss of HBsAg with appearance of anti-HBs.

### Treatment of chronic hepatitis B

Two major types of antiviral drugs are being used for the treatment of chronic HBV: drugs that directly interfere with virus replication and drugs that modulate the HBV-specific immune response. Nucleoside and nucleotide analogues, such as lamivudine, adefovir and entecavir, directly inhibit reverse

transcriptase and thereby impair viral replication. Interferon (IFN) has marked immunomodulatory, but less pronounced direct antiviral effects. Registered treatment for chronic HBV in most countries currently consists of interferon-alpha, lamivudine, adefovir, peginterferon- $\alpha$ -2a and entecavir, of which the last two have recently been approved. Approval of entecavir for the treatment of chronic HBV in Europe is expected on the short term. Advantages and limitations of, and response to a one-year course of treatment with these antiviral agents, as well as factors influencing likelihood of response, are shown in tables 3 and 4.

## IMMUNOMODULATORY DRUGS

### Pegylated interferon- $\alpha$

Interferon-alpha (IFN- $\alpha$ ) was licensed for the treatment of chronic hepatitis B in most countries in the early 1990s. Interferons are naturally occurring cytokines with immunomodulatory, antiproliferative and antiviral properties.<sup>46</sup>

In HBeAg-positive patients IFN- $\alpha$  results in loss of HBeAg in 25 to 40% of patients.<sup>44,47-52</sup> The majority of patients have a durable response; reactivation occurs in 10 to 20% of patients.<sup>44,53,54</sup> Standard IFN- $\alpha$  induced responses are less durable in HBeAg-negative chronic HBV, with sustained response in 10 to 47% (average 24%) at 12 months after cessation of therapy.<sup>55,59</sup> Long-term follow-up studies showed better overall survival and lower incidence of hepatic decompensation and HCC in responders to IFN- $\alpha$  therapy.<sup>44,45,54,60</sup>

The addition of a polyethylene glycol (PEG) molecule to IFN significantly prolongs half-life and results in more sustained IFN activity. Two pegylated IFNs have been studied for the treatment of HBV, a large branched 40kDa PEG linked to IFN  $\alpha$ -2a (peginterferon  $\alpha$ -2a) and a small linear 12kDa PEG linked to IFN  $\alpha$ -2b (peginterferon  $\alpha$ -2b).<sup>61</sup> Both these interferons were initially investigated for the treatment of chronic hepatitis C infection and have shown similar tolerability and higher rates of sustained viral response compared with conventional IFN.<sup>62,63</sup> Peginterferon-alpha-2a (PEG-IFN  $\alpha$ -2a) has recently been registered for the treatment of chronic HBV in Europe and the United States and should be given by subcutaneous injection once weekly for 48 weeks in a dosage of 180 microgram in both HBeAg-positive and HBeAg-negative patients. Results of treatment with PEG-IFN during shorter periods are very limited. Peginterferon-alpha-2b (PEG-IFN  $\alpha$ -2b) will only be registered in specific east-Asian countries.

In HBeAg-positive patients treatment with PEG-IFN was found superior to conventional IFN, with loss of HBeAg in 35% and seroconversion to anti-HBe in 29 to 32% of patients.<sup>32,64,66</sup> Long-term follow-up of patients treated with PEG-IFN and lamivudine combination therapy showed

**Table 3.** Comparison of drugs approved for the treatment of chronic hepatitis B

Treatment	Advantage	Disadvantage	HBeAg positive		HBeAg negative	
			HBeAg seroconversion		HBV DNA negativity	
			EOT	EOFU	EOT	EOFU
Alpha-interferon	Finite treatment course No drug resistance	Frequent subcutaneous injection Frequent adverse events Contraindicated in advanced cirrhosis High costs	35% (44, 47-51)*	30% (44, 47-51, 53, 65)	60% (55-59, 119, 120)*	35% (55-59)*
Peginterferon	Finite treatment course Weekly dosage interval No drug resistance	Subcutaneous injection Frequent adverse events Contraindicated in advanced cirrhosis High costs	40% (32, 64-66)*	35% (32, 64-67)*	63% (68)*	19% (68)*
Lamivudine	Oral administration Good tolerability Low costs	Long duration of treatment High incidence of antiviral resistance	19% (74-78)*	12% (67, 83, 84)*	65% (68, 85, 87)*	10% (68, 86)*
Adefovir	Oral administration Low incidence of antiviral resistance	Long duration of treatment Weak antiviral effect Renal toxicity	12% (93)*	NA	51% (95)*	NA
Entecavir	Oral administration Strongest HBV inhibitor Good tolerability Low incidence of antiviral resistance	Long duration of treatment High costs	21% (102)*	NA	90% (103)*	NA

This table shows mean response rates (HBeAg seroconversion for HBeAg-positive patients and undetectable HBV DNA for HBeAg-negative patients) at the end of treatment (EOT) with various antiviral drugs for 48 to 52 weeks and at the end of follow-up (EOFU) (NA = data not available). Response to therapy is less durable in HBeAg-negative patients compared with HBeAg-positive patients. Further, while (PEG-)IFN associated responses are generally durable, relapse occurs in a large proportion of nucleos(t)ide analogue treated patients after discontinuation of therapy. \*References.

**Table 4.** Predictors of response to antiviral therapy in HBeAg-positive patients

Treatment	Decreased likelihood of response	Increased likelihood of response
(Peg)interferon	Baseline ALAT $\leq 2 \times \text{ULN}^{119}$ Baseline HBV DNA $>10^9 \text{ c/ml}^{64}$ Genotype C or D <sup>31-33</sup> HIV coinfection <sup>121</sup>	Baseline ALAT $>2 \times \text{ULN}^{119}$ Baseline HBV DNA $\leq 10^9 \text{ c/ml}^{64}$ Genotype A or B <sup>31-33</sup>
Nucleoside analogues	Baseline ALAT $\leq 2 \times \text{ULN}^{81}$ HAI $0-9^{81}$	Baseline ALAT $>2 \times \text{ULN}^{81}$ HAI $\geq 10^{81}$

This table shows baseline factors influencing likelihood of response to antiviral therapy in HBeAg-positive patients. ALAT = alanine aminotransferase; HBV = hepatitis B virus; ULN = upper limit of normal; HAI = histological activity index.


durable response at 72 weeks post-treatment in over 80% of responders.<sup>67</sup> In HBeAg-negative HBV only one large randomised controlled trial using PEG-IFN has been conducted so far.<sup>68</sup> At the end of follow-up, a combined response, with suppression of serum HBV DNA below  $10^4 \text{ c/ml}$  and normalisation of ALAT, was observed in 36% of patients. HBsAg seroconversion occurs in 3 to 7% of PEG-IFN treated patients, which represents 10 to 20% of virological responders.<sup>32,64,68</sup> HBV genotype appears to predict response to PEG-IFN, with a higher probability of HBeAg loss and HBsAg loss for patients with genotype A (47 and 14%) and B (44 and 9%) compared with genotype C (28% and 3%) and D (25 and 2%).<sup>32,65,69</sup> Addition of a nucleoside analogue to

PEG-IFN therapy does not increase response rates in either HBeAg-positive or HBeAg-negative patients, as has earlier been shown in conventional IFN therapy.<sup>32,64,68,70</sup>

Interferon can have several side effects including influenza-like symptoms, fatigue, headache, myalgia, gastrointestinal symptoms (nausea, anorexia, weight loss), alopecia and local reaction at the injection site. These side effects are frequently observed, but rarely lead to discontinuation of treatment. More serious adverse events such as myelosuppression, neuropsychiatric symptoms (irritability, depression and insomnia), neurological symptoms and thyroid dysfunction may require dose reduction or discontinuation.<sup>71,72</sup> Use of PEG-IFN is not recommended in advanced liver disease

since it may potentially precipitate immunological flares and liver failure in these patients (figure 2).<sup>73</sup> Adverse events observed during treatment with PEG-IFN are similar to those observed with conventional IFN. The proportion of patients requiring discontinuation of treatment for safety reasons was comparable for PEG-IFN and standard IFN.

**Figure 2.** Host and virus induced flares associated with interferon therapy



This figure shows serum HBV DNA (○) and ALAT (●) levels during and after (peg)interferon (IFN) therapy. IFN potentially induces immunological flares and liver failure: 1. Host-induced flare, with elevation in serum ALAT followed by a decrease in viral load. 2. Virus-induced flare, where serum ALAT elevation is preceded by an increase in serum HBV DNA.<sup>122</sup>

## NUCLEOS(T)IDE ANALOGUES

### Lamivudine

Lamivudine was the first nucleoside analogue licensed for the treatment of chronic HBV. Lamivudine is a cytosine analogue and inhibits reverse transcriptase by competing for incorporation into growing DNA chains causing chain termination. Lamivudine can be taken orally in a dosage of 100 mg daily, is generally well tolerated and has an excellent safety profile.

HBeAg seroconversion with HBV DNA <10<sup>5</sup> c/ml occurs in 16 to 22% of patients by one year compared with 4 to 13% of untreated controls.<sup>74-79</sup> Higher cumulative HBeAg-seroconversion rates were observed with increased duration of lamivudine treatment, with 29% at two years, 40% at three years, and 47% at four years of therapy.<sup>76,79,80</sup> Reduction of serum HBV DNA occurs in 98% of patients.<sup>75</sup> Elevated ALAT >2 x ULN was found to be the best predictor of response to lamivudine.<sup>81</sup> Lamivudine treatment may be discontinued if HBV DNA is suppressed below

levels detectable by non-PCR assays and seroconversion from HBeAg to anti-HBe has been achieved. However, lamivudine-induced HBeAg seroconversion is significantly less durable than HBeAg seroconversion following IFN-containing therapies.<sup>82</sup> Data on durability of response to lamivudine are limited, HBeAg seroconversion has been reported to be durable in 50 to 77% of patients.<sup>83,84</sup> Prolonged duration of ongoing lamivudine therapy after HBeAg seroconversion and low pretreatment HBV DNA seem to be associated with decreased relapse rates.<sup>83</sup>

In HBeAg-negative patients serum HBV DNA was undetectable by PCR assay in 68 to 73% of patients after one year of lamivudine therapy. At this time point 73 to 96% of patients showed biochemical response.<sup>68,85,86</sup> However, relapse occurred in 66 to 85% of patients after discontinuation of treatment. In patients treated continuously over one year, response rates progressively declined to about 67% after two years, 60% after three years and 39% after four years.<sup>85,87,88</sup>

Prolonged lamivudine treatment can be used to prevent adverse clinical outcome in patients with advanced liver disease (bridging fibrosis or cirrhosis). Disease progression, defined as a two-point increase in Child-Turcotte-Pugh score, and development of HCC were found to be significantly decreased in lamivudine treated patients compared with untreated controls.<sup>42</sup>

The major drawback of lamivudine, which significantly limits its use as first-line therapy, is the high rate of occurrence of viral resistance. The majority of patients with virological breakthrough show mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the polymerase gene.<sup>88</sup> The most important mutation is a substitution of valine or isoleucine for methionine at position 204 (rtM204V/I).<sup>89</sup> In many patients this is accompanied by a second mutation substituting methionine for leucine in an upstream region (rtL180M). Lamivudine resistance is more likely to occur in patients with high baseline serum HBV DNA levels and patients with HBV DNA >10<sup>3</sup> c/ml after six months of treatment.<sup>90</sup> The frequency of resistance increases with the duration of treatment from 24% at one year to 38% at two years, 50% at three years and 67% at four years.<sup>79,80,87</sup> The emergence of lamivudine-resistant mutants is usually associated with an increase in serum HBV DNA and ALAT, and selection of YMDD variants has been associated with worsening of liver histology.<sup>91</sup>

### Adefovir dipivoxil

Adefovir dipivoxil is the oral prodrug of adefovir and has activity against both wild-type and lamivudine-resistant HBV.<sup>92</sup> Adefovir is a nucleotide analogue of adenosine monophosphate and acts as a competitive inhibitor and chain terminator of viral replication. Adefovir at the dose of 10 mg daily is well tolerated and has a good safety profile.<sup>93</sup>

In HBeAg-positive patients, serum HBV DNA levels  $<10^3$  c/ml and normalisation of ALAT were observed in 21 and 48% of treated patients, compared with 0 and 16% of untreated controls after one year of adefovir therapy, respectively. HBeAg seroconversion occurred in 12% of patients receiving adefovir compared with 6% in the placebo group.<sup>93</sup> Continued adefovir therapy over one year increased rates of HBeAg seroconversion to 29% after two years and 43% after three years. A similar increase in the proportion of patients with HBV DNA  $<10^3$  c/ml was observed, to 45 and 56% of patients after 96 and 144 weeks, respectively.<sup>94</sup>

In HBeAg-negative patients, treatment with adefovir for one year resulted in serum HBV DNA  $<10^3$  c/ml and normalisation of ALAT in 51 and 72% of treated patients, compared with 0 and 29% of untreated controls.<sup>95</sup> The percentage of HBeAg-negative patients with HBV DNA  $<10^3$  c/ml was 71% at two years and 67% at five years, and ALAT normalised in 73 and 69%, respectively.<sup>96,97</sup> Prolonged adefovir therapy significantly improved liver histology compared with baseline in up to 75 to 80% of patients after five years.<sup>96</sup> Response to adefovir is generally not durable after discontinuation of treatment.<sup>95,97</sup>

Resistance to adefovir is less common and occurs later in the course of HBV treatment compared with lamivudine. To date, mutations in the polymerase gene that have been confirmed to confer resistance to adefovir include rtN236T and rtA181V.<sup>98</sup> The rtN236T mutation occurs most frequently and is associated with the selection of a novel asparagine to threonine substitution at residue rt236 in the domain D of the HBV polymerase.<sup>97</sup> The rtA181V mutation involves a substitution of alanine by valine or threonine at position rt181 of the B domain of the HBV polymerase. The cumulative probability of adefovir resistance is 0 and 28% at one and five years, respectively.<sup>96</sup>

### Entecavir

Entecavir is a guanosine analogue and a potent inhibitor of the HBV polymerase. Entecavir has activity against both wild-type and lamivudine resistant HBV. Entecavir can be taken orally, is well tolerated and safe at daily dosages up to 1 mg.<sup>99,100</sup> Entecavir has recently been approved by the FDA for the treatment of chronic hepatitis B and should be given in a dosage of 0.5 mg daily in nucleoside analogue naive patients and 1 mg in lamivudine-refractory patients.<sup>100,101</sup>

In both HBeAg-positive and HBeAg-negative naive patients, one year of entecavir (0.5 mg daily) was found to be superior to lamivudine therapy in reducing serum HBV DNA (6.9 vs 5.4 log for HBeAg-positive and 5.0 vs 4.5 log for HBeAg-negative patients, respectively) and histological improvement.<sup>102,103</sup> HBeAg seroconversion, HBV DNA negativity by PCR assay and normalisation of ALAT were observed in 21, 67 and 68% of HBeAg-positive patients treated with entecavir for 48 weeks, respectively.<sup>102</sup> Prolonging entecavir therapy to 96 weeks resulted in HBeAg

seroconversion in 31% and HBV DNA  $<10^2$  c/ml in 80% of patients, respectively.<sup>104</sup> In HBeAg-negative patients HBV DNA negativity by PCR assay occurred in 90% of patients, while 78% of patients had normalisation of ALAT at week 48.<sup>103</sup> In lamivudine-refractory patients treatment with entecavir 1 mg daily was superior to 0.5 mg daily, and resulted in HBeAg seroconversion in 4%, HBV DNA  $<10^2$  c/ml in 26% and normalisation of ALAT in 68% of patients, respectively.<sup>101</sup> Based on these results, entecavir appears to be a stronger inhibitor of HBV than either lamivudine or adefovir.

Entecavir resistance requires pre-existing lamivudine resistance and additional changes at residue rtT184, rtS202 or rtM250 of the HBV reverse transcriptase.<sup>105</sup> Resistance to entecavir was not observed in nucleoside analogue naive patients treated with entecavir for 48 weeks or 96 weeks.<sup>106-108</sup> In lamivudine-refractory HBV resistance to entecavir has not been described after one year of therapy. However, changes at the rtT184 and/or rtS202 residue were observed in 10% of patients after two years of entecavir treatment.<sup>109</sup>

### NEW DRUGS

Emtricitabine is structurally similar to lamivudine (3TC) and has potent antiviral activity against HBV and human immunodeficiency virus (HIV). Seroconversion from HBeAg to anti-HBe can be observed in 12 to 23% of patients after 48 weeks, increasing to 33% after 96 weeks of treatment.<sup>104,110</sup> In HBeAg-negative patients serum HBV DNA was  $<10^4$  c/ml in 76 and 71% of patients after 48 weeks and 96 weeks of treatment, respectively.<sup>104</sup> Mutations associated with resistance to emtricitabine were observed in 12 and 18% of patients after 48 weeks and 96 weeks of treatment, respectively.<sup>104</sup> With the advent of newer antiviral agents with significantly lower risk of antiviral resistance, emtricitabine will possibly have a minor role as monotherapy for HBV.

Telbivudine is an L-nucleoside analogue, which is more potent than lamivudine in suppressing HBV DNA.<sup>111</sup> Serum HBV DNA was undetectable by PCR assay in 61% of patients at week 52, while HBeAg seroconversion occurred in 31% of patients. Combination of telbivudine with lamivudine did not result in increased response rates. Resistance to telbivudine emerged in 5% of patients after one year of therapy. Ongoing phase III trials will help determine the role of telbivudine in the treatment of chronic HBV.

Tenofovir disoproxil fumarate is an acyclic nucleotide analogue and has been approved for the treatment of HIV infection. Dosage of tenofovir for hepatitis B infection is 300 mg daily. Tenofovir seems more potent in suppression of HBV DNA than adefovir, with HBV DNA undetectable by PCR assay in all patients treated with tenofovir compared with 44% of patients treated with adefovir at week 48.<sup>112</sup> Currently, randomised controlled trials comparing tenofovir and adefovir are being performed.

## ANTIVIRAL RESISTANCE

The highest incidence antiviral resistance has been reported during lamivudine treatment,<sup>80</sup> while resistance to adefovir and entecavir is less common.<sup>96,105</sup> During nucleoside analogue treatment, close monitoring for antiviral resistance is advised, since hepatitis flares have been reported following lamivudine resistance. Antiviral resistance should be suspected if rebound of viral replication (1 log<sub>10</sub> increase in serum HBV DNA) occurs in a fully compliant patient after initial response, antiviral resistance testing should then be considered (figure 3). It is still being debated whether combination nucleoside analogue treatment should be given, as for HIV infection, or subsequent introduction in case of nonresponse or resistance should be used. Prolonged combination therapy after emergence of antiviral resistance does not seem beneficial.<sup>113</sup> However, whether a shorter overlap period of combination therapy is preferable in patients with advanced liver disease before discontinuing initial treatment has not been assessed. Sequential monotherapy may facilitate resistance to other drugs and may ultimately lead to multiresistance.<sup>109</sup> Following that rationale, lamivudine treatment may negatively influence future treatment options due to the high incidence of antiviral resistance. Furthermore, a recent study showed decreased responsiveness of lamivudine-resistant patients to a course of PEG-IFN.<sup>114</sup> Using lamivudine as initial therapy is therefore highly questionable. Currently adefovir is preferable as first-line nucleoside analogue therapy

because of its favourable resistance profile. Entecavir and tenofovir seem to be the drugs with most potent anti-HBV activity and lowest rate of antiviral resistance discovered to date and may become the new standard in nucleos(t)ide analogue treatment for chronic hepatitis B.


## VIRAL SUPPRESSION OR IMMUNE MODULATION?

The approach to treatment of hepatitis B has rapidly changed over the past decade. The treatment landscape has advanced with the availability of multiple new antiviral agents. However, despite this major progress, long-term off-treatment control has not been achieved in a large proportion of patients. Worldwide, evidence-based treatment guidelines for the management of chronic hepatitis B have been developed.<sup>3,22,115</sup> These documents make few specific recommendations as to whether pegylated interferon or nucleoside analogues should be used as first-line therapy. Because both approaches have proven effective, but also have advantages and limitations, the question arises what treatment regime should be used as first-line therapy. The major difference between these treatment strategies is providing sustained off-treatment response with a finite treatment course (IFN) vs therapy-maintained response (nucleoside analogues).

Of currently available antiviral agents, peginterferon-based therapies result in the highest probability of sustained off-treatment response. On the other hand, treatment with nucleoside analogues over prolonged periods is feasible and viral and biochemical response can generally be maintained. Since response to these agents is generally not durable after discontinuation of therapy, it is currently proposed that nucleoside analogue therapy needs to be continued indefinitely. This subsequently imposes a considerable risk for antiviral resistance. In our opinion, these findings provide a strong argument in favour of immunomodulatory therapy as first-line treatment for chronic hepatitis B.

Irrespective of the type of antiviral therapy used, sustained virological response results in improved biochemical, histological and clinical outcome. The main goal of antiviral therapy in chronic hepatitis B therefore remains achieving sustained viral suppression, preferably with a finite course of therapy. Individual patient characteristics such as age, comorbid disorders and likelihood to tolerate potential side effects should also be included in deciding on the optimal treatment regime.

Since PEG-IFN results in the highest rates of off-treatment response, treatment with this drug should be considered as first-line therapy in eligible patients with a high likelihood of response. This includes HBeAg-positive patients with genotype A or B, serum ALAT more than twice the upper limit of normal



and moderate HBV DNA levels ( $10^5$  to  $10^8$  c/ml). Although data on PEG-IFN in HBeAg-negative chronic HBV are limited, PEG-IFN therapy may also be preferential in these patients. For patients with a low likelihood of response to or not eligible for PEG-IFN therapy, patients not tolerating PEG-IFN therapy, or with persistent hepatic inflammation and high viral load after a one-year course of PEG-IFN, treatment with nucleoside analogues should be considered. For several patient groups nucleoside analogues are the antiviral drug of choice. This includes patients with advanced cirrhosis, patients starting chemotherapy,<sup>116</sup> immunocompromised patients,<sup>117</sup> and pregnant patients with very high HBV DNA levels ( $>10^9$  c/ml).<sup>118</sup>

## REFERENCES

- Kane M. Global programme for control of hepatitis B infection. *Vaccine* 1995;13 Suppl 1:S47-9.
- Lee WM. Hepatitis B virus infection. *N Engl J Med* 1997;337(24):1733-45.
- De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). *J Hepatol* 2003;39(suppl 1):S3-25.
- Wong SN, Lok AS. Treatment of hepatitis B: who, when, and how? *Arch Intern Med* 2006;166(1):9-12.
- Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. *J Hepatol* 2002;36(2):263-70.
- De Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. *Gastroenterology* 1992;103(5):1630-5.
- Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. *J Hepatol* 1990;10(1):29-34.
- Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. *Hepatology* 1987;7(1):20-3.
- Sanchez-Tapias JM, Costa J, Mas A, Pares A, Bruguera M, Rodes J. Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B. *J Hepatol* 1988;6(1):15-22.
- Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. *Gut* 2003;52(3):416-9.
- Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. *Gut* 1991;32(3):294-8.
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349(9055):825-32.
- Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *Hepatology* 1998;27(3):868-72.
- Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006;130(3):678-86.
- Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). *J Hepatol* 1994;21(4):656-66.
- Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. *Hepatology* 1995;21(1):77-82.
- Bruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. *J Hepatol* 2003;39(suppl 1):S59-63.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004;127(5 suppl 1):S35-50.
- Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med* 2002;347(3):168-74.
- Iloeje UH, Yang HI, Su J, et al. Viral load is a strong predictor of hepatocellular carcinoma risk in people chronically infected with hepatitis B virus and with normal serum alanine aminotransferase level. *J Viral Hepat* 2005;42(suppl 2):179.
- Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006;295(1):65-73.
- Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2001;34(6):1225-41.
- Arauz-Ruiz P, Norder H, Robertson BH, Magnus LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. *J Gen Virol* 2002;83(8):2059-73.
- Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? *Hepatology* 2004;40(4):790-2.
- Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. *J Gen Virol* 2000;81(1):67-74.
- Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003;37(1):19-26.
- Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000;118(3):554-9.
- Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. *Gastroenterology* 2002;122(7):1756-62.
- Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002;123(6):1848-56.
- Kumar A, Kumar SI, Pandey R, Naik S, Aggarwal R. Hepatitis B virus genotype A is more often associated with severe liver disease in northern India than is genotype D. *Indian J Gastroenterol* 2005;24(1):19-22.
- Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. *Gut* 2005;54(7):1009-13.
- Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. *Lancet* 2005;365(9454):123-9.
- Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. *Hepatology* 2002;36(6):1425-30.
- Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. *J Hepatol* 2002;36(2):303-4.
- Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. *Annu Rev Immunol* 1995;13:29-60.
- Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. *Hepatology* 2003;38(1):4-13.
- Ferrari C, Missale G, Boni C, Urbani S. Immunopathogenesis of hepatitis B. *J Hepatol* 2003;39(suppl 1):S36-42.
- Tang TJ, Kwekkeboom J, Mancham S, et al. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. *J Hepatol* 2005;43(1):45-52.
- Chisari FV. Cytotoxic T-cells and viral hepatitis. *J Clin Invest* 1997;99(7):1472-7.

40. Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. *Am J Gastroenterol* 2003;98(10):2261-7.
41. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. *Ann Intern Med* 2002;137(1):1-10.
42. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004;351(15):1521-31.
43. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. *Hepatology* 2004;39(3):857-61.
44. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004;39(3):804-10.
45. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996;334(22):1422-7.
46. Hara M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. *Drugs* 1995;50(5):873-96.
47. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. *Ann Intern Med* 1991;114(8):629-34.
48. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. *Gastroenterology* 1988;95(5):1318-25.
49. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. *N Engl J Med* 1990;323(5):295-301.
50. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999;30(1):238-43.
51. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. *Ann Intern Med* 1993;119(4):312-23.
52. Janssen HL, Berk L, Schalm SW, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. *Gut* 1992;33(8):1094-8.
53. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. *J Viral Hepat* 1998;5(6):389-97.
54. Janssen HL, van Zonneveld M, Schalm SW. Hepatitis B. *N Engl J Med* 2004;350(26):2719-20.
55. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. *Hepatology* 1997;26(6):1621-5.
56. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. *J Hepatol* 1990;11(suppl 1):S133-6.
57. Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. *J Hepatol* 1992;14(2-3):221-5.
58. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. *Hepatology* 1992;15(4):584-9.
59. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. *Gastroenterology* 2001;120(7):1828-53.
60. Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. *J Viral Hepat* 2004;11(4):349-57.
61. Craxi A, Cooksley WG. Pegylated interferons for chronic hepatitis B. *Antiviral Res* 2003;60(2):87-9.
62. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358(9286):958-65.
63. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347(13):975-82.
64. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2005;352(26):2682-95.
65. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. *J Viral Hepat* 2003;10(4):298-305.
66. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. *Ann Intern Med* 2005;142(4):240-50.
67. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. *Hepatology* 2005;41(6):1357-64.
68. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2004;351(12):1206-17.
69. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-Interferon alpha-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype. *Am J Gastroenterol* 2006;101(2):297-303.
70. Janssen HL, Berk L, Heijink RA, ten Kate FJ, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. *Hepatology* 1993;17(3):383-8.
71. van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. *Aliment Pharmacol Ther* 2005;21(9):1163-71.
72. Janssen HL, Berk L, Vermeulen M, Schalm SW. Seizures associated with low-dose alpha-interferon. *Lancet* 1990;336(8730):1580.
73. Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). *BMJ* 1993;306(6870):107-8.
74. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999;341(17):1256-63.
75. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *N Engl J Med* 1998;339(2):61-8.
76. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. *Gastroenterology* 2000;119(1):172-80.
77. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. *Gut* 2000;46(4):562-8.
78. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. *J Hepatol* 2003;38(6):818-26.
79. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. *Hepatology* 2001;33(6):1527-32.
80. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2004;19(11):1276-82.
81. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. *Hepatology* 2002;36(1):186-94.

Buster, et al. Antiviral treatment for chronic hepatitis B virus infection.

82. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. *Gut* 2003;52(3):420-4.
83. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. *Hepatology* 2000;32(4 Pt 1):803-6.
84. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. *Hepatology* 2003;37(4):748-55.
85. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 2000;32(4 Pt 1):847-51.
86. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. *J Hepatol* 2000;32(2):300-6.
87. Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. *J Viral Hepat* 2001;8(4):270-5.
88. Gaia S, Marzano A, Smedile A, et al. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. *Aliment Pharmacol Ther* 2004;20(3):281-7.
89. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. *Hepatology* 1996;24(3):714-7.
90. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. *Hepatology* 2001;34(4 Pt 1):785-91.
91. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. *J Hepatol* 2005;42(2):173-9.
92. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. *Hepatology* 2000;32(1):129-34.
93. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003;348(9):808-16.
94. Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Xiong S. Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. 55<sup>th</sup> AASLD meeting 2004, Abstract 1135.
95. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 2003;348(9):800-7.
96. Hadziyannis S, Tassopoulos NC, Chang TT, et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: Results after 5 years of therapy. *Hepatology* 2005;42(suppl 1):754A.
97. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. *N Engl J Med* 2005;352(26):2673-81.
98. Bartholomeusz A, Locarnini SA, Ayres A, et al. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. *Hepatology* 2004;40(suppl 1):A165.
99. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. *Hepatology* 2001;34(3):578-82.
100. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. *Gastroenterology* 2002;123(6):1831-8.
101. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. *Gastroenterology* 2005;129(4):1198-209.
102. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006;354(10):1001-10.
103. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. *N Engl J Med* 2006;354(10):1011-20.
104. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. *J Hepatol* 2005;43(1):60-6.
105. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. *Antimicrob Agents Chemother* 2004;48(9):3498-507.
106. Chang TT, Gish RG, De Man RA, Gadano A, Sollano J, Han KH, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naive patients. *Hepatology* 2004;40(suppl 1):193A.
107. Gish RG, Chang TT, De Man RA, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). *Hepatology* 2005;42(suppl 1):267A.
108. Shouval D, Lai CL, Cheinquer H, et al. Entecavir demonstrates superior histologic and virological efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase-III trial ETV-027. *Hepatology* 2004;40(suppl 1):728A.
109. Colonno R, Rose RE, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. *Hepatology* 2005;42(suppl 1):573A.
110. Lim SG, Ng TM, Kung N, et al. A Double-blind Placebo-Controlled Study of Emtricitabine in Chronic Hepatitis B. *Arch Intern Med* 2006;166(1):49-56.
111. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. *Gastroenterology* 2005;129(2):528-36.
112. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. *Hepatology* 2004;40(6):1421-5.
113. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. *Gastroenterology* 2004;126(1):91-101.
114. Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. *J Hepatol* 2006;44(3):507-11.
115. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. *Liver Int* 2005;25(3):472-89.
116. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. *J Clin Oncol* 2004;22(5):927-34.
117. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. *Blood* 2002;100(2):391-6.
118. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. *J Viral Hepat* 2003;10(4):294-7.
119. Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. *Gastroenterology* 1992;102(6):2091-7.
120. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. *Gastroenterology* 2001;121(1):101-9.
121. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. *Gastroenterology* 2002;123(6):1812-22.
122. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon [alpha]-2b therapy. *Gut* 2005;54(11):1604-9.